

**Frontiers in Transplantation**  
*Clinical Excellence through Innovation*

29<sup>th</sup> and 30<sup>th</sup> of September 2022



Hosted by:  
**King's College London**  
**DAY BRIEF**

**Day 1 – Thursday 29<sup>th</sup> of September 2022**

- |               |   |
|---------------|---|
| 9.00 – 9.30   | <b>Check In / Registration</b>  |
| 9.30 – 10.00  | <b>Innate Immunity in Transplantation</b> - Steve Sacks                                 |
| 10.00 – 10.30 | <b>Allorecognition</b> - Robert Lechler   |
| 10.30 – 11.00 | <b>Role of Exosomes in alloimmunity</b> - Lesley Smythe                                 |
| 11.00 – 11.15 | <b>Live Q&amp;A session</b>   |
| 11.15 – 11.30 | <b>BREAK</b>  |
| 11.30 – 12.00 | <b>Tregs – Basic Biology</b> - Cristiano Scotta   |
| 12.00 – 12.30 | <b>Importance of metabolic pathways</b> – Nilou Safinar                                 |
| 12.30 – 13.00 | <b>Antibody-mediated Rejection – what happens when Ab binds endothelium</b> - A Dorling |
| 13.00 – 13.15 | <b>Live Q&amp;A session</b>   |
| 13.15 – 14.00 | <b>BREAK</b>  |
| 14.00 – 14.30 | <b>Cytotoxic Inhibition of complement – EMPIRIKAL trials 1 and 2</b> - Steve Sacks      |
| 14.30 – 15.00 | <b>Cytotoxic inhibition of thrombin</b> - A Dorling                                     |
| 15.00 – 15.15 | <b>Live Q&amp;A session</b>   |
| 15.15 – 15.30 | <b>BREAK</b>  |
| 15.30 – 16.00 | <b>Ex Vivo Normothermic perfusion</b> - Chris Callaghan                                 |
| 16.00 – 16.30 | <b>KCL trials in chronic rejection</b> - A Dorling                                      |
| 16.30 – 17.00 | <b>Live Q&amp;A session</b>   |

## Day 2 – Friday 30<sup>th</sup> of September 2022

### Polyclonal T cell therapy

- 09.00 – 09.30 **Check In / Registration**
- 09.30 – 10.00 **The ONE Study** - David Game
- 10.00 – 10.30 **ThriL** - Alberto Sanchez-Fueyo
- 10.30 – 11.00 **Polyclonal Tregs to suppress HLA memory responses** - Caroline Dudrueilh
- 11.00 – 11.30 **Live Q&A session**
- 11.30 – 12.00 **BREAK**

### Expanding endogenous Treg populations

- 12.00 – 12.30 **Low dose interleukin 2 therapy in liver transplantation** - Alberto Sanchez-Fueyo
- 12.30 – 13.00 **Biology of IL-2 therapy – contrasting results in transplantation vs. autoimmunity** - Tim Tree
- 13.00 – 13.15 **Live Q&A session**
- 13.15 – 13.30 **BREAK**

### Next generation Treg therapy

- 14.00 – 14.30 **CAR T cells in cancer therapy** - John Maher
- 14.30 – 15.00 **CAR Tregs to promote transplantation tolerance** - Giovanna Lombardi
- 15.00 – 15.30 **Commercialising Treg technology – benefits vs pitfalls** - Luke Henry – Quell Therapeutics
- 15.30 – 15.45 **Live Q&A session**
- 15.45 – 16.00 **BREAK**
- 16.00 – 17.00 **Guest lecture Guest speaker** – Menna Clatworthy, University of Cambridge
- 17.00 **Closing** – Giovanna Lombardi and Anthony Dorling

